Skip to main content
Clinical Trials/NCT01865396
NCT01865396
Completed
N/A

Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.

University Ghent1 site in 1 country268 target enrollmentApril 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
Life-limiting Cancer With Prognosis of Approximately 1 Year
Sponsor
University Ghent
Enrollment
268
Locations
1
Primary Endpoint
Quality of life of the patient and his family caregiver at 12 weeks.
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The World Health Organization (WHO) defines palliative care as an approach to improve the quality of life of patients and their families facing life-threatening illness, through prevention and relief of pain and of physical, psychosocial and spiritual problems. The WHO stresses that palliative care is applicable early in the course of the illness together with other therapies that are intended to cure or prolong life, such as chemotherapy or radiation therapy. For the benefit of the patient, palliative care is however often given (too) late in the course of the disease of incurably ill patients.

The aim of our study is to measure the effect of interventional palliative care on quality of life, mood and end-of-life care of patients with advanced cancer and their families. These patients have a limited life expectancy and a high symptom burden, this leads us to suggest that these patients may be benefited with palliative care soon after diagnosis of metastatic disease (interventional palliative care).

The research design of this study is a randomized controlled trial with, on the one hand, an intervention group in which patients and their families receive interventional palliative care in combination with standard cancer care and on the other hand a control group in which patients and their families receive only standard oncologic care. Participants in the intervention group will meet the palliative support team shortly after diagnosis. Afterwards, the palliative support will meet them at least once a month. This intervention focuses on topics such illness understanding, symptom management, decision making and coping with the disease. Participants in the control group will only meet with the palliative support team at the patient's own request or after referral by the oncologist or the nursing staff.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
April 2017
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with life-limiting cancer (prognosis of approximately 1 year) are eligible if:
  • Patients are within 12 weeks of referral from an other hospital after receiving first line treatment or within 8 to 12 weeks of a new diagnosis (histological and cytological confirmed):
  • Metastatic and advanced pancreatic, stomach, oesophageal and biliary tract adenocarcinoma;
  • Metastatic or advanced NSCLC (stage IIIB or IV) or metastatic SCLC,
  • Malignant pleural mesothelioma
  • Metastatic or advanced head and neck cancer (stage III or IV)
  • Patients are within 12 weeks of progression after receiving treatment and have an prognosis of approximately 1 year:
  • Metastatic and locally advanced colorectal cancer, with progression after second line treatment
  • Metastatic or advanced prostate carcinoma, after second line treatment
  • Advanced breast cancer with visceral and/or brain metastasis, with progression on second or third line treatment

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Quality of life of the patient and his family caregiver at 12 weeks.

Time Frame: at 12 weeks

This will be measured with validated questionnaires (EORTC-QLQ C30, McGill QoL, SF-36).

Quality of life of the patient and his family caregiver, 6-weekly after 12 weeks.

Time Frame: 6-weekly after 12 weeks

This will be measured with validated questionnaires (EORTC-QLQ C30, McGill QoL, SF-36).

Quality of life of the patient and his family caregiver at baseline.

Time Frame: at baseline

This will be measured with validated questionnaires(EORTC-QLQ C30, McGill QoL, SF-36).

Secondary Outcomes

  • Influence of palliative care on mood and illness-understanding of patients and family caregivers at baseline.(at baseline.)
  • Influence of palliative care on the decision of physicians with regards to end-of-life-care.(after death of patient)
  • Influence of palliative care on mood and illness-understanding of patients and family caregivers 6-weekly, after 12 weeks.(6-weekly, after 12 weeks.)
  • Influence of palliative care on mood and illness-understanding of patients and family caregivers at 12 weeks.(at 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials